[go: up one dir, main page]

CL2013001368A1 - Composicion farmaceutica que comprende carbidopa y al menos un 4% de levodopa, arginina y opcionalmente meglumina; composicion liquida que comprende arginina y entacapona o tolcapona; proceso para prepararla y uso en un trastorno neurologico o de movimiento. - Google Patents

Composicion farmaceutica que comprende carbidopa y al menos un 4% de levodopa, arginina y opcionalmente meglumina; composicion liquida que comprende arginina y entacapona o tolcapona; proceso para prepararla y uso en un trastorno neurologico o de movimiento.

Info

Publication number
CL2013001368A1
CL2013001368A1 CL2013001368A CL2013001368A CL2013001368A1 CL 2013001368 A1 CL2013001368 A1 CL 2013001368A1 CL 2013001368 A CL2013001368 A CL 2013001368A CL 2013001368 A CL2013001368 A CL 2013001368A CL 2013001368 A1 CL2013001368 A1 CL 2013001368A1
Authority
CL
Chile
Prior art keywords
arginine
tolcapone
entacapone
carbidopa
levodopa
Prior art date
Application number
CL2013001368A
Other languages
English (en)
Inventor
Oron Yacoby-Zeevi
Mara Nemas
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of CL2013001368A1 publication Critical patent/CL2013001368A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CL2013001368A 2010-11-15 2013-05-15 Composicion farmaceutica que comprende carbidopa y al menos un 4% de levodopa, arginina y opcionalmente meglumina; composicion liquida que comprende arginina y entacapona o tolcapona; proceso para prepararla y uso en un trastorno neurologico o de movimiento. CL2013001368A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41363710P 2010-11-15 2010-11-15
US201161524064P 2011-08-16 2011-08-16

Publications (1)

Publication Number Publication Date
CL2013001368A1 true CL2013001368A1 (es) 2014-09-05

Family

ID=45478410

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001368A CL2013001368A1 (es) 2010-11-15 2013-05-15 Composicion farmaceutica que comprende carbidopa y al menos un 4% de levodopa, arginina y opcionalmente meglumina; composicion liquida que comprende arginina y entacapona o tolcapona; proceso para prepararla y uso en un trastorno neurologico o de movimiento.

Country Status (27)

Country Link
US (7) US9421267B2 (es)
EP (3) EP2640358B1 (es)
JP (3) JP5902705B2 (es)
KR (1) KR101859242B1 (es)
CN (2) CN103442693A (es)
AU (1) AU2011330757B2 (es)
BR (1) BR112013011685B1 (es)
CA (1) CA2817888C (es)
CL (1) CL2013001368A1 (es)
CY (1) CY1120005T1 (es)
DK (2) DK2640358T3 (es)
ES (2) ES2776734T3 (es)
HR (2) HRP20180514T1 (es)
HU (2) HUE047841T2 (es)
IL (1) IL263954A (es)
LT (1) LT2640358T (es)
MX (1) MX348225B (es)
NZ (1) NZ610911A (es)
PL (2) PL3326615T3 (es)
PT (2) PT3326615T (es)
RS (1) RS57047B1 (es)
RU (2) RU2740080C2 (es)
SG (2) SG10201509316SA (es)
SI (1) SI2640358T1 (es)
SM (1) SMT201800145T1 (es)
WO (1) WO2012066538A1 (es)
ZA (1) ZA201303509B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102438587B (zh) 2009-05-19 2015-08-19 神经层有限公司 用于多巴脱羧酶抑制剂连续施用的组合物
ES2673219T3 (es) 2010-11-15 2018-06-20 Neuroderm Ltd Composición para la entrega transdérmica de agentes activos
MX348225B (es) 2010-11-15 2017-05-31 Neuroderm Ltd Administracion continua de levodopa, inhibidores de dopa decarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para la misma.
EP3456315A1 (en) 2012-06-05 2019-03-20 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
WO2014141261A1 (en) * 2013-03-13 2014-09-18 Neuroderm Ltd Method for treatment of parkinson's disease
JP6528281B2 (ja) * 2014-01-29 2019-06-12 国立研究開発法人産業技術総合研究所 シクロデキストリンの利用による抗がん活性が増強されたアシュワガンダ葉の水抽出物の調製方法、及びアシュワガンダ葉を含む医薬組成物
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
HUE064818T2 (hu) * 2014-03-13 2024-04-28 Neuroderm Ltd Dopa dekarboxiláz inhibitor készítmények
FI3782617T3 (fi) 2014-09-04 2024-03-13 Lobsor Pharmaceuticals Ab Farmaseuttisia geelikoostumuksia, jotka käsittävät levodopaa, karbidopaa ja entakaponia
CN111454290B (zh) 2014-10-21 2022-12-23 艾伯维公司 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
JP2018514516A (ja) 2015-03-30 2018-06-07 ベルリレム ゲーエムベーハー 水溶性ｌ‐ドーパエステル
DK3075723T3 (en) 2015-03-30 2017-09-11 Berlirem Gmbh High-resolution L-DOPA glycerol esters
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
EP3445346A1 (en) * 2016-04-20 2019-02-27 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
CN106619490A (zh) * 2017-01-19 2017-05-10 云南白药集团无锡药业有限公司 一种左旋多巴透皮贴剂及其制备方法
EP4445953A3 (en) 2017-06-05 2025-01-29 Dizlin Pharmaceuticals AB Levodopa infusion solution
RU2021139906A (ru) 2017-07-07 2022-04-26 Нейродерм Лтд Устройство для подкожной доставки текучего лекарственного средства
EP3768263A1 (en) 2018-03-23 2021-01-27 LobSor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
AU2019379806A1 (en) 2018-11-15 2021-05-27 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
CN111643493B (zh) * 2020-05-26 2023-01-10 上海京新生物医药有限公司 一种高浓度左旋多巴制剂及其制备方法及其应用
CN111701024B (zh) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用
EP4203939A4 (en) * 2020-08-31 2024-11-06 Purdue Pharma L.P. Compositions and methods for levodopa delivery
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
EP4460289A1 (en) * 2022-01-03 2024-11-13 Neuroderm, Ltd. Methods and compositions for treating parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808317A (en) * 1969-10-29 1974-04-30 Alcon Labor Inc Stabilized aqueous borate complexes of biologically active catechol amines
US3936495A (en) 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (ja) * 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
DE3779500T2 (de) 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4684666A (en) 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
US4963568A (en) * 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5350769A (en) 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6245917B1 (en) 1998-03-20 2001-06-12 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
KR100602047B1 (ko) 1998-05-15 2006-07-19 워너-램버트 캄파니 엘엘씨 감마-아미노부티르산 유도체의 안정화된 제약 제제 및그의 제조 방법
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7479498B2 (en) 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
WO2002047670A1 (en) * 2000-12-15 2002-06-20 Pfizer Limited Treatment of male sexual dysfunction
EP1450901A4 (en) 2001-12-10 2005-05-25 Bristol Myers Squibb Co (1-PHENYL-2-HETEROARYL) ETHYL-GUANIDINE COMPOUNDS AS AN INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE
EA200401334A1 (ru) 2002-04-11 2005-04-28 Ранбакси Лабораторис Лимитед Фармацевтические композиции карбидопы и леводопы с контролируемым высвобождением
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
DE10247233A1 (de) * 2002-10-10 2004-06-17 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen, die Topoisomerase IV inhibieren
CA2500320A1 (en) * 2002-10-10 2004-04-29 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Novel compounds with antibacterial activity
US20050147687A1 (en) 2003-07-18 2005-07-07 Julia Rashba-Step Methods for fabrication, uses and compositions of small spherical particles of AAT prepared by controlled phase separation
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US20050053669A1 (en) * 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
JP2007509976A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン 増加された鉄の吸収のための組成物及び投与形態
WO2005099678A1 (en) * 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2006037061A2 (en) 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
EP1809283A2 (en) * 2004-10-01 2007-07-25 The Research Foundation Of State University Of New York Morphine and morphine precursors
DE102006021872B4 (de) * 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20080051459A1 (en) * 2006-05-31 2008-02-28 Solvay Pharmaceuticals Gmbh Long term 24-hour intestinal administration of levodopa/carbidopa
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
WO2008124330A2 (en) 2007-04-06 2008-10-16 Transform Pharmaceuticals, Inc. Systems and methods for delivering a fluid drug
CN101669925B (zh) 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
CN102438587B (zh) 2009-05-19 2015-08-19 神经层有限公司 用于多巴脱羧酶抑制剂连续施用的组合物
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
KR101187064B1 (ko) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
ES2673219T3 (es) 2010-11-15 2018-06-20 Neuroderm Ltd Composición para la entrega transdérmica de agentes activos
MX348225B (es) 2010-11-15 2017-05-31 Neuroderm Ltd Administracion continua de levodopa, inhibidores de dopa decarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para la misma.
KR20140035325A (ko) 2010-12-10 2014-03-21 신애질 코포레이션 피하의 불용융성 레보도파 프로드러그 조성물들 및 주입 방법들
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
WO2014141261A1 (en) 2013-03-13 2014-09-18 Neuroderm Ltd Method for treatment of parkinson's disease
HUE064818T2 (hu) 2014-03-13 2024-04-28 Neuroderm Ltd Dopa dekarboxiláz inhibitor készítmények

Also Published As

Publication number Publication date
PT2640358T (pt) 2018-02-23
CA2817888C (en) 2018-12-11
CY1120005T1 (el) 2018-12-12
NZ610911A (en) 2015-02-27
ES2660772T3 (es) 2018-03-26
LT2640358T (lt) 2018-03-26
US9421267B2 (en) 2016-08-23
CN103442693A (zh) 2013-12-11
BR112013011685B1 (pt) 2022-03-03
US20140249229A1 (en) 2014-09-04
KR20130140075A (ko) 2013-12-23
PT3326615T (pt) 2020-03-23
DK2640358T3 (en) 2018-04-16
EP2640358A1 (en) 2013-09-25
US9040578B2 (en) 2015-05-26
US20140249228A1 (en) 2014-09-04
US20250114315A1 (en) 2025-04-10
AU2011330757B2 (en) 2016-05-26
BR112013011685A2 (pt) 2016-08-09
US20170157077A1 (en) 2017-06-08
ZA201303509B (en) 2014-12-23
WO2012066538A1 (en) 2012-05-24
RU2016147575A (ru) 2018-10-23
MX2013005493A (es) 2013-09-06
KR101859242B1 (ko) 2018-05-17
HRP20200366T1 (hr) 2020-07-10
ES2776734T3 (es) 2020-07-31
AU2011330757A1 (en) 2013-06-06
RU2740080C2 (ru) 2021-01-11
RU2607497C2 (ru) 2017-01-10
EP3326615B1 (en) 2020-01-08
US9040577B2 (en) 2015-05-26
JP2018030877A (ja) 2018-03-01
SI2640358T1 (en) 2018-05-31
CN110123743A (zh) 2019-08-16
EP3326615A1 (en) 2018-05-30
US20230047523A1 (en) 2023-02-16
RU2016147575A3 (es) 2020-03-04
JP2016106146A (ja) 2016-06-16
HRP20180514T1 (hr) 2018-05-04
MX348225B (es) 2017-05-31
EP3692982A1 (en) 2020-08-12
US20200397730A1 (en) 2020-12-24
JP6387171B2 (ja) 2018-09-05
PL3326615T3 (pl) 2020-07-27
SMT201800145T1 (it) 2018-05-02
JP2013545745A (ja) 2013-12-26
HUE047841T2 (hu) 2020-05-28
SG190258A1 (en) 2013-06-28
EP2640358B1 (en) 2018-01-03
JP5902705B2 (ja) 2016-04-13
US20140051755A1 (en) 2014-02-20
DK3326615T3 (da) 2020-03-09
IL263954A (en) 2019-01-31
SG10201509316SA (en) 2015-12-30
HUE037005T2 (hu) 2018-08-28
RU2013123457A (ru) 2014-12-27
PL2640358T3 (pl) 2018-06-29
RS57047B1 (sr) 2018-05-31
CA2817888A1 (en) 2012-05-24
JP6231145B2 (ja) 2017-11-15

Similar Documents

Publication Publication Date Title
CL2013001368A1 (es) Composicion farmaceutica que comprende carbidopa y al menos un 4% de levodopa, arginina y opcionalmente meglumina; composicion liquida que comprende arginina y entacapona o tolcapona; proceso para prepararla y uso en un trastorno neurologico o de movimiento.
BR112013028365A2 (pt) "composição líquida compreendendo adi, composto compreendendo adi ligada covalentemente através de grupo de ligação a polietilenoglicol e uso de adi no preparo de composição para tratamento de câncer".
BR112014000236A2 (pt) lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
BR112013022927A2 (pt) composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
WO2012074930A3 (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
BR112012012446A2 (pt) "concentrado alimentar temperado, processo, uso, composição alimentar pronta para consumo e usp de um poliol líquido"
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
BR112014019750A2 (pt) composto, composlção farmacêutlca, método para aumentar a lnclusão de éxon 7 de smn2 em mrna, método para aumentar a quantidade de proteína smn e método para tratar sma em um indivíduo humano em necessidade
IL216383A (en) Stable pharmaceutical preparations containing arginine, levodopa and carbidopa
CL2015000420A1 (es) Anticuerpo de unión a gfr alfa 3 (gfra3); ácido nucleico que lo codifica; vector; método para producirlo; composición farmacéutica que lo comprende; y uso para tratar una afección o enfermedad relacionada con gfra3.
SG10201510236XA (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112015000534A2 (pt) método para a preparação de 2,4-dihidroxibutirato, microrganismo, organismo e uso
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
BR112013014441A2 (pt) microrganismo tendo uma melhor capacidade de produzir ornitina e método para produzir ornitina usando o mesmo
BR112013001423A2 (pt) método, método in vitro, uso e kit útil para realizar o método
ZA201205836B (en) Use of levodopa,carbidopa and entacapone for treating parkinson's disease
GT201100205A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
CL2014000948A1 (es) Profarmaco de adrenomedulina basado en polietilenglicol; procedimiento de preparacion; composicion farmaceutica que lo comprende; y su uso para tratar y/o prevenir trastornos cardiovasculares, edematosos y/o inflamatorios.
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
CL2013000801A1 (es) Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia